Genes, chromosomes & cancer · 2017
HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Urbini Milena, Astolfi Annalisa, Pantaleo Maria Abbondanza, Serravalle Salvatore, Dei Tos Angelo Paolo, Picci Piero, Indio Valentina, Sbaraglia Marta, Benini Stefania, Righi Alberto, Gambarotti Marco, Gronchi Alessandro, Colombo Chiara, Dagrada Gian Paolo, Pilotti Silvana, Maestro Roberta, Polano Maurizio, Saponara Maristella, Tarantino Giuseppe, Pession Andrea, Biasco Guido, Casali Paolo Giovanni, Stacchiotti Silvia
Аннотация
Extraskeletal myxoid chondrosarcoma (EMC) is a very rare sarcoma most often arising in the soft tissue. Rare EMC of the bone have been reported. EMC exhibits distinctive clinico-pathological and genetic features; however, despite the name, it lacks any feature of cartilaginous differentiation. EMC is characterized by the rearrangement of the NR4A3, which, in most cases (about 62-75%), is fused with EWSR1 and less frequently with other partners, including TAF15 (27%), TCF12 (4%), TFG, and FUS. We herein report the identification by whole-transcriptome sequencing of HSPA8 as a novel fusion partner of NR4A3 in a case of EMC. FISH analysis confirmed the presence of a genomic HSPA8-NR4A3 translocation in the vast majority of tumor cells. Our findings expand the spectrum of NR4A3 fusion partners involved in EMC pathobiology.